alexa [DSAEK for the treatment of endothelial disease: results in the initial 100 cases].
Surgery

Surgery

Journal of Transplantation Technologies & Research

Author(s): Busin M

Abstract Share this page

Abstract PURPOSE: To evaluate the learning curve and the outcome of Descemet Automated Endothelial Keratoplasty (DSAEK) in patients with primary or secondary endothelial decompensation. METHODS: DSAEK was performed in 100 eyes with endothelial decompensation (Fuchs' Dystrophy n = 59; pseudophakic bullous keratopathy n = 33; failed corneal graft n = 8). All patients underwent a standard procedure including the following steps: Descemet membrane and endothelium removal from the recipient cornea under air; inferior peripheral iridectomy; microkeratome-assisted preparation of a donor lamella consisting of deep stroma and endothelium (between 100 and 200 micron in thickness), which is punched to desired size (8.5 to 9 mm) from the endothelial side; graft delivery with a specially designed glide; complete anterior chamber air fill to obtain firm attachment of the donor lamella and air-tight closure of all surgical wounds. In 46 cases phacoemulsification with implantation of an intraocular lens into the capsular bag was combined with DSAEK surgery. Visual acuity, refraction and endothelial cell count were evaluated prospectively at 1, 3, 6, and 12 months after DSAEK. RESULTS: As early as 1 month after surgery 76 of 100 patients had a best spectacle-corrected visual acuity (BSCVA) better than or equal to 0.5, with a refractive astigmatism within 1.5 Diopters (D). One year after surgery, 79 of 100 patients had a BSCVA better than or equal to 0.5, with a refractive astigmatism within 1.5 D. At this examination time 11 of 100 patients could see 1.0 or better and the average endothelial cell loss amounted to 22.5 +/- 4.2 \%. CONCLUSIONS: DSAEK surgery allows fast visual rehabilitation of patients with decompensated endothelium. Visual outcome is superior to that of conventional penetrating keratoplasty (PK) in terms of BSCVA and early stabilization. Endothelial cell loss also compares favourably to that recorded after PK. This article was published in Klin Monbl Augenheilkd and referenced in Journal of Transplantation Technologies & Research

Relevant Expert PPTs

Relevant Speaker PPTs

  • Abulkhair Beatti
    A new understanding of interferential current energy transfer in tissue
    PPT Version | PDF Version
  • Hisham Hussein Imam
    Pregnancy after renal transplantation
    PPT Version | PDF Version
  • Dhanya Mohan
    Refractory anemia due to parvovirus b19 infection in a renal transplant recipient
    PPT Version | PDF Version
  • Ana Laura Pimentel
    Glycated hemoglobin in the screening and diagnosis of renal post-transplantation diabetes
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • William Lindsey
    Ultra-refined Follicular Unit Transplantation into scar tissue as an alternative to surgical scar revision in hair bearing scalp
    PPT Version | PDF Version
  • Rajaram Samant
    GainmoreTM M: An oral supplementation in men with Androgenic Alopecia for reduction in hair loss & new hair growth
    PPT Version | PDF Version
  • U Vineetha
    Evaluation of rice transplanter at different age of seedlings and spacings (Kubota model)
    PPT Version | PDF Version
  • Kazuhiro Ikegame
    Graft-versus-GVHD, a second transplantation from another donor for the rescue from refractory acute GVHD
    PPT Version | PDF Version
  • Qiurong Li
    Therapeutic modulation and reestablishment of the intestinal microbiota with fecal microbiota transplantation resolves sepsis and diarrhea in a patient
    PPT Version | PDF Version
  • Andreea Iftimia-Mander
    Umbilical Cord Blood Transplantation: Understanding what are the critical quality attributes (CQAs) of a cord blood unit.
    PPT Version | PDF Version
  • Jack Sung
    Progenic Hair Regrowth Treatment
    PPT Version | PDF Version
  • D K Agarwal
    Impact of renal transplantation on psychosocial status of HIV positive patients
    PPT Version | PDF Version
  • Dave Ray
    Nutrition & HAIR & SCALP DIALOGUE
    PPT Version | PDF Version
  • Alexandra Dalu
    What solutions to hair loss?
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords